3-[(2-Methylpropan-2-yl)oxycarbonylamino]-6-oxo-6-phenylmethoxyhexanoic acid | 218943-30-7

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 谷氨酸类衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-[(2-Methylpropan-2-yl)oxycarbonylamino]-6-oxo-6-phenylmethoxyhexanoic acid
• CAS: 218943-30-7
• 化学式: C₁₈H₂₅NO₆
• 分子量: 351.4
• InChiKey: JABNOCWCLLYHKE-UHFFFAOYSA-N

物化性质

• 沸点：
  530.0±45.0 °C(Predicted)
• 密度：
  1.178±0.06 g/cm3(Predicted)
• 溶解度：
  溶于氯仿、二氯甲烷、乙酸乙酯、DMSO、丙酮等。

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  25
• 可旋转键数：
  11
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  102
• 氢给体数：
  2
• 氢受体数：
  6

安全信息

• 危险等级：
  IRRITANT
• WGK Germany：
  3
• 海关编码：
  29242990
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

制备方法与用途

用途：生化试剂（非天然氨基酸）

文献信息

• [EN] QUATERNARY ASSEMBLIES OF WATER-SOLUBLE NON-PEPTIDE HELICAL FOLDAMERS, THEIR USE AND PRODUCTION THEREOF<br/>[FR] ENSEMBLES QUATERNAIRES DE FOLDAMÈRES HÉLICOÏDAUX NON PEPTIDIQUES SOLUBLES DANS L'EAU, LEUR UTILISATION ET LEUR PRODUCTION
  申请人：CENTRE NAT DE LA RECH SCIENT (CNRS)

  公开号：WO2017037150A1

  公开（公告）日：2017-03-09

  The present description provides compositions and methods for producing therapeutic oligomeric compounds. In another aspect the description provides methods for administering the oligomeric compounds for the treatment and prevention of disease in a mammal. In particular, the disclosure relates to medicaments comprising various novel oligomeric compounds and pharmaceutically acceptable salts thereof. The compounds of the disclosure may optionally be administered with at least one of a pharmaceutically acceptable excipient, additional pharmacologically active agent or a combination thereof.

  本描述提供了用于生产治疗性寡聚合物化合物的组合物和方法。另一方面，描述提供了用于在哺乳动物中治疗和预防疾病的寡聚合物化合物的给药方法。具体而言，该披露涉及包含各种新型寡聚合物化合物及其药用可接受盐的药物。该披露的化合物可以选择与至少一种药用可接受的赋形剂、额外的药理活性剂或二者的组合一起给药。
• [EN] FOLDAMER HELIX BUNDLE-BASED MOLECULAR ENCAPSULATION<br/>[FR] ENCAPSULATION MOLÉCULAIRE FONDÉE SUR DES FAISCEAUX HÉLICOÏDAUX DE FOLDAMÈRES
  申请人：CENTRE NAT DE LA RECH SCIENT (CNRS)

  公开号：WO2017037142A1

  公开（公告）日：2017-03-09

  The present description provides compositions and methods for producing therapeutic oligomeric compounds. In another aspect the description provides methods for administering the oligomeric compounds for the treatment and prevention of disease in a mammal. In particular, the disclosure relates to medicaments comprising various novel oligomeric compounds and pharmaceutically acceptable salts thereof. The compounds of the disclosure may optionally be administered with at least one of a pharmaceutically acceptable excipient, additional pharmacologically active agent or a combination thereof.

  本文描述了制备治疗性寡聚化合物的组合物和方法。另一方面，本文提供了在哺乳动物中治疗和预防疾病的寡聚体化合物的给药方法。具体而言，本文涉及包含各种新型寡聚化合物及其药学上可接受的盐的药物。本文所述的化合物可以选择性地与药学上可接受的赋形剂、额外的药理活性剂或两者的组合一起给药。
• QUATERNARY ASSEMBLIES OF WATER-SOLUBLE NON-PEPTIDE HELICAL FOLDAMERS, THEIR USE AND PRODUCTION THEREOF
  申请人：Centre National de la Recherche Scientifique CNRS

  公开号：EP3138851A1

  公开（公告）日：2017-03-08

  The present description provides compositions and methods for producing therapeutic oligomeric compounds. In another aspect the description provides methods for administering the oligomeric compounds for the treatment and prevention of disease in a mammal. In particular, the disclosure relates to medicaments comprising various novel oligomeric compounds and pharmaceutically acceptable salts thereof. The compounds of the disclosure may optionally be administered with at least one of a pharmaceutically acceptable excipient, additional pharmacologically active agent or a combination thereof.

  本说明提供了生产治疗性低聚化合物的组合物和方法。在另一方面，本说明提供了施用低聚化合物治疗和预防哺乳动物疾病的方法。特别是，本公开涉及包含各种新型低聚化合物及其药学上可接受的盐的药物。本公开的化合物可选择与至少一种药学上可接受的赋形剂、额外的药理活性剂或它们的组合一起施用。
• Foldamer helix bundle-based molecular encapsulation
  申请人：UREKA SARL

  公开号：US10233213B2

  公开（公告）日：2019-03-19

  The present description provides compositions and methods for producing therapeutic oligomeric compounds. In another aspect the description provides methods for administering the oligomeric compounds for the treatment and prevention of disease in a mammal. In particular, the disclosure relates to medicaments comprising various novel oligomeric compounds and pharmaceutically acceptable salts thereof. The compounds of the disclosure may optionally be administered with at least one of a pharmaceutically acceptable excipient, additional pharmacologically active agent or a combination thereof.

  本说明提供了生产治疗性低聚化合物的组合物和方法。在另一方面，本说明提供了施用低聚化合物治疗和预防哺乳动物疾病的方法。特别是，本公开涉及包含各种新型低聚化合物及其药学上可接受的盐的药物。本公开的化合物可选择与至少一种药学上可接受的赋形剂、额外的药理活性剂或它们的组合一起施用。
• FOLDAMER HELIX BUNDLE-BASED MOLECULAR ENCAPSULATION
  申请人：UREKA SARL

  公开号：US20180244718A1

  公开（公告）日：2018-08-30

  The present description provides compositions and methods for producing therapeutic oligomeric compounds. In another aspect the description provides methods for administering the oligomeric compounds for the treatment and prevention of disease in a mammal. In particular, the disclosure relates to medicaments comprising various novel oligomeric compounds and pharmaceutically acceptable salts thereof. The compounds of the disclosure may optionally be administered with at least one of a pharmaceutically acceptable excipient, additional pharmacologically active agent or a combination thereof.